Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Moodys
McKinsey
AstraZeneca
Colorcon

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Urelumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Urelumab: Sponsors, patents, clinical trial progress

Urelumab is an investigational drug.

There have been 7 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, and M.D. Anderson Cancer Center.

There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.

Recent Clinical Trials for Urelumab
TitleSponsorPhase
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsClinica Universidad de Navarra, Universidad de NavarraPhase 1/Phase 2
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerBristol-Myers SquibbPhase 1
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for CancerUniversity of ChicagoPhase 1

See all Urelumab clinical trials

Clinical Trial Summary for Urelumab

Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab

See all Urelumab clinical trials

US Patents for Urelumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Urelumab   See Pricing Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   See Pricing
Urelumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Urelumab   See Pricing Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   See Pricing
Urelumab   See Pricing Methods and compositions for treating conditions associated with an abnormal inflammatory responses First Wave Bio, Inc. (Ann Arbor, MI)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Urelumab

Drugname Country Document Number Estimated Expiration Related US Patent
Urelumab Argentina 102536 2034-11-05   See Pricing
Urelumab Australia 2015342940 2034-11-05   See Pricing
Urelumab Brazil 112017008568 2034-11-05   See Pricing
Urelumab Canada 2964290 2034-11-05   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Johnson and Johnson
Merck
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.